SUNDAY 14TH - TUESDAY 16TH JULY 2019
The Manchester Cancer Research Centre (MCRC) and the Experimental Cancer Medicine Centres (ECMC) network will be hosting a three-day conference on Phase I, at Hilton Deansgate, in Manchester city centre.
Our keynote speakers include Professor Lillian Siu (Princess Margaret Hospital, Toronto) and Skip Burris (Sarah Cannon Research Institute, Nashville).
The programme can be viewed here.
We are pleased to confirm that this conference has received accreditation by the Federation of the Royal Colleges of Physicians of the United Kingdom and as such attendees will be eligible for up to 18 category 1 (external) CPD credits. Certificates of attendance will be issued by email at the end of the conference.
We would like to thank our sponsors:
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life, safety and survival of patients. Twenty-nine medicines developed by Roche are included in the WHO Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy. Roche in the UK employs over 2,000 people in pharmaceuticals and diagnostics.
For more information: www.roche.co.uk
Founded in 2016 Carrick Therapeutics is aiming is to create the leading European based biopharmaceutical oncology company. Focusing on innovative research Carrick Therapeutics has a patient focused vision to serve cancer patients around the world by the introduction of ground breaking therapies that will transform the way cancer is treated. Working in partnership with like-minded scientists, collaborators and investors the company has two oncology therapeutics under evaluation in clinical trials - CT7001 and CT900.
CT7001 is a first in class orally bio-available Cyclin-dependent Kinase 7 (CDK7) selective inhibitor, that has shown striking efficacy in multiple pre-clinical cancer models and is in phase 1 clinical development. CT900 is a targeted therapy that combines targeting folate receptor α (FRα) and inhibiting thymidylate synthase. The small molecule compound selectively enters cancer cells that over express folate receptor FRα and patients may be selected via a companion diagnostic based on FRα expression. A lead development program in ovarian cancer is underway.
Founded in 2003, Athenex, Inc. is a global clinical stage biopharmaceutical company dedicated to becoming a leader in the discovery, development and commercialization of next generation drugs for the treatment of cancer. Athenex is organized around three platforms, including an Oncology Innovation Platform, a Commercial Platform and a Global Supply Chain Platform. The Company’s current clinical pipeline is derived from four different platform technologies: (1) Orascovery, based on non-absorbed P-glycoprotein inhibitor, (2) Src kinase inhibition, (3) T-cell receptor-engineered T-cells (TCR-T), and (4) Arginine deprivation therapy.
Athenex’s employees worldwide are dedicated to improving the lives of cancer patients by creating more active and tolerable treatments. Athenex has offices in Buffalo and Clarence, New York; Cranford, New Jersey; Houston, Texas; Chicago, Illinois; Hong Kong; Taipei, Taiwan; and multiple locations in Chongqing, China.
For more information, please visit www.athenex.com.
Menarini Silicon Biosystems, based in Bologna, Italy, and Huntingdon Valley (PA), USA, develops technologies and products that help researchers understand the biological complexity of disease through the study of single cells. The company manufactures and markets the DEPArray NxT, the only image-based digital cell-sorting and isolation platform that enables clinical researchers to conduct molecular analyses on fixed cells with single-cell precision. In 2017 Menarini Silicon Biosystems purchased all the assets and relevant business related to the CELLSEARCH® Circulating Tumor Cell (CTC) System. The integration of CELLSEARCH and DEPArray provides an end-to-end workflow solution* for the enumeration, isolation, and molecular characterization of CTCs from a simple blood test in the clinical research setting. This will help drive the clinical utility and correlation of CTCs with the effectiveness of specific therapies.
*The workflow described is for research use only. Not for use in diagnostic procedures.
Conference Dinner Partner
Sarah Cannon Research Institute is one of the world’s leading clinical research organizations conducting community-based clinical trials throughout the United States and United Kingdom. Sarah Cannon’s network of strategic sites includes hundreds of physicians who engage in research. With a focus on advancing therapies for patients, the organization has led more than 300 first-in-man clinical trials since its inception in 1993, and has been a clinical trial leader in the majority of approved cancer therapies over the last 10 years.
Additionally, Sarah Cannon offers management, regulatory, and other research support services for drug development and industry sponsors through its contract research organization (CRO), Sarah Cannon Development Innovations. As the CRO of Sarah Cannon, it leverages expert physician leadership to design and implement clinical trials that effectively and efficiently lead to rapid clinical development decisions.
If you have any enquiries about the conference, please contact Rachel Chown.